

PRESENTATION OUTLINE

- Review of the year
- Financial results
- Trading performance
- Outlook
- Questions





DAVID KNEALE

REVIEW OF THE YEAR

- Middle income consumers remain under pressure
- Minimal real growth in private healthcare market
- Health and beauty markets continue to be promotionally driven
- Selling price inflation constrained
- Better second half performance in Clicks
- UPD total turnover managed up 43.9% to R11.5 billion
- Diluted headline earnings per share up 9.2%



MICHAEL FLEMING

FINANCIAL HIGHLIGHTS

- Group turnover up 13.6%
 - Clicks turnover up 8.6%
 - UPD turnover up 22.8%
 - Selling price inflation of 2.6%
- Operating margin down from 6.6% to 6.3%
- Diluted headline EPS up 9.2% to 298.6 cps
- Cash generated by operations R1.4 billion
- Total dividend of 168.0 cps, up 10.5%
- Return on equity of 55.6%

TURNOVER

| R'm | 2013 | 2012 | % change | % same store growth | % inflation |
|---------------------|---------|---------|-------------|---------------------|----------------|
| Clicks | 11 293 | 10 401 | 8.6 | 5.8 | 3.1 |
| Musica | 862 | 872 | (1.0) | 5.9 | 2.6 |
| The Body Shop | 137 | 123 | 11.3 | 6.3 | 2.2 |
| Total retail | 12 292 | 11 396 | 7.9 | 5.8 | 3.1 |
| UPD | 7 710 | 6 277 | 22.8 | | 1.8 |
| Intragroup turnover | (2 459) | (2 236) | 10.0 | | |
| Total group | 17 543 | 15 437 | 13.6 | | 2.6 |

- Volume growth in all businesses
- UPD benefited from new preferred supplier contracts

TOTAL INCOME

| | 2013 R' m | 2012 R'm | % change | 2013 % margin | 2012 % margin |
|--------------|--------------|-------------|-------------|------------------|------------------|
| Retail | 4 097 | 3 764 | 8.9 | 33.3 | 33.0 |
| Distribution | 655 | 559 | 17.1 | 8.5 | 8.9 |
| Intragroup | (56) | (47) | | | |
| Total group | 4 696 | 4 276 | 9.8 | 26.8 | 27.7 |

- Private label margin growth and well managed promotional activity in Clicks
- UPD margin impacted by supplier mix
- Group margin impacted by stronger growth in UPD

OPERATING EXPENDITURE - RETAIL

| R'm | 2013 | 2012 | % change |
|-------------------------------|-------|-------|----------|
| Depreciation and amortisation | 181 | 155 | 16.9 |
| Occupancy costs | 495 | 468 | 5.8 |
| Employment costs | 1 605 | 1 425 | 12.6 |
| Other operating costs | 910 | 863 | 5.5 |
| Total retail costs | 3 191 | 2 911 | 9.6 |

- Continuing investment in stores and IT
- Pharmacy professional costs up 25.8%
- Comparable retail costs up 7.8%

OPERATING EXPENDITURE - DISTRIBUTION

| R'm | 2013 | 2012 | % change |
|-------------------------------|------|------|----------|
| Depreciation and amortisation | 19 | 17 | 16.3 |
| Occupancy costs | 7 | 5 | 36.2 |
| Employment costs | 185 | 157 | 17.7 |
| Other operating costs | 249 | 224 | 11.2 |
| Total distribution costs | 460 | 403 | 14.3 |

- Additional variable bulk distribution costs
- Temporary warehouse costs
- Comparable costs up 6.1%

OPERATING PROFIT

| | 2013 R'm | 2012 R' m | % change | 2013 % margin | 2012 % margin |
|--------------|-------------|--------------|-------------|------------------|------------------|
| Retail | 907 | 852 | 6.3 | 7.4 | 7.5 |
| Distribution | 195 | 157 | 24.2 | 2.5 | 2.5 |
| Intragroup | 2 | 2 | | | |
| Total group | 1 104 | 1 011 | 9.1 | 6.3 | 6.6 |

- Margins within target ranges, despite investment in pharmacy and UPD distribution
- Group margin impacted by mix

INVENTORY

| | Days in stock* | | Inventory (R'm) | | <u>m)</u> |
|----------------------|----------------|------|-----------------|-------|-----------|
| | 2013 | 2012 | 2013 | 2012 | % change |
| Retail | 68 | 69 | 1 613 | 1 522 | 6.0 |
| Distribution | 30 | 34 | 619 | 567 | 9.0 |
| Intragroup inventory | | | (7) | (9) | |
| Total group | 59 | 63 | 2 225 | 2 080 | 7.0 |

- UPD inventory normalised with annualisation of preferred supply contract
- Inventory growth contained below turnover growth

^{*} At cost price

CASH GENERATION

| R'm | 2013 | 2012 |
|---|-------|-------|
| Profit before tax | 1 051 | 958 |
| Non-cash adjustments | 300 | 277 |
| Operating profit before working capital changes | 1 351 | 1 235 |
| Working capital changes | 26 | (161) |
| Net interest and tax paid | (364) | (310) |
| Cash inflow from operations | 1 013 | 764 |

32.6% increase in cash from operations

CASH UTILISATION

| R'm | 2013 | 2012 |
|-----------------------------|-------|-------|
| Cash inflow from operations | 1 013 | 764 |
| Capital expenditure | (310) | (256) |
| Dividends paid | (394) | (337) |
| Share buy-backs | (354) | (12) |
| Other investing activities | 5 | 8 |
| Other financing activities | 130 | (159) |
| Net cash generated | 90 | 8 |

CAPITAL MANAGEMENT

- Group will remain cash generative
- Investing in the business R338m capex planned in FY2014
 - R182m stores
 - R88m IT systems
 - R38m UPD
 - R30m other
- Return balance of cash to shareholders
 - Dividend cover 1.8 times
 - Continued share buy-backs

MEDIUM-TERM FINANCIAL TARGETS

| | 2013 – 2015 target | Achieved in 2013 | 2014 – 2016 target |
|----------------------------|-----------------------|------------------|-----------------------|
| ROE (%) | 55 – 65 | 55.6 | 50 – 60 |
| ROA (%) | 14 – 18 | 14.8 | 14 – 18 |
| Inventory days | 55 – 60 | 59 | 55 – 60 |
| Group operating margin (%) | 6.0 - 7.0 | 6.3 | 6.0 – 7.0 |
| Retail | 7.0 – 8.0 | 7.4 | 7.0 – 8.0 |
| UPD | 2.2 – 2.7 | 2.5 | 2.2 – 2.7 |





DAVID KNEALE

SALES PERFORMANCE



| | % change | % contribution |
|--------------------------|----------|----------------|
| Pharmacy | 10.8 | 25.9 |
| Front shop health | 15.9 | 21.7 |
| Beauty and personal care | 6.1 | 32.4 |
| General merchandise | 2.7 | 20.0 |
| Total turnover | 8.6 | 100.0 |

- Improved performance in second half up 10%
- Promotional activity increased from 23% to 26% of sales, with no margin impact


PHARMACY



Dynalex

- Continued switch to generics +16.1%
 - 40.3% of sales
- Trend to self-medication
 - OTC medicines +14.1%
 - 223 000 Discovery MedSaver/ HealthyCare members
- Total volume growth +10.8%
- Pharmacy staff turnover down from 37% to 28%
- Market share





MICLICKS

Co-Flem

Uniflex



FRONT SHOP HEALTH



Good growth in key categories

Front shop medicines +12.1%

Vitamins and supplements +11.4%

Baby +27.6%

- Broadening product ranges
- Space increased by 9.6%
- Market share



| % | 2013 | 2012 |
|---------------------|------|------|
| Front shop health** | 39.6 | 38.5 |
| Baby** | 9.9 | 8.4 |

^{**} Per AC Nielsen (restated)

BEAUTY AND PERSONAL CARE



- Highly competitive markets
- Promotions key to driving sales
 - Fragrance +13.0%
 - Colour cosmetics +6.5%
 - Skincare +6.4%
- Slower growth in haircare +1.5%
 - Lack of product innovation in Caucasian haircare
- Market share

| % | 2013 | 2012 |
|------------|------|------|
| Skincare** | 34.4 | 34.1 |
| Haircare** | 30.5 | 30.2 |

^{**} Per AC Nielsen (restated)

GENERAL MERCHANDISE



- Improvement in homeware +1.5%
 - Up 3.9% in second half
 - Ranges being refreshed
- Good performance in convenience categories
 - Confectionery +9.6%
 - Domestics +16.4%









CUSTOMERS AND STORES




- ClubCard membership now 4.1m
 - 76.1% of sales
 - 225 000 members of Baby Club
- Private label maintained at 18.4% of sales
 - Front shop at 24.1%
 - 54 private label medicines on shelf
- 331 dispensaries in 442 stores at year end
 - 25 new stores in FY2014
 - 20 25 new pharmacies in FY2014
- Rated 1st in health and beauty*



^{*} Per TNS Brand Tracker









PERFORMANCE



| | | | Market share* | |
|------------|----------|----------------|---------------|-------|
| | % change | % contribution | 2013 | 2012 |
| CDs | (6.5) | 44.3 | 46.2% | 43.7% |
| DVDs | 2.6 | 27.3 | 29.5% | 27.7% |
| Gaming | (14.7) | 14.5 | 7.3% | 9.8% |
| Technology | 38.5 | 13.9 | | |

- Continued market share gains in CDs and DVDs
- Reduced focus on lower margin gaming category
- Good growth in technology
- Net closure of 14 stores 3 more closures planned in FY2014
- Opportunity to gain further share and grow technology

^{*} Per Aquidneck/GfK

PERFORMANCE

THE BODY SHOP.

- Higher income customers proving more resilient
- Good sales performance
 - New skincare and make-up launches
 - Good gifting ranges
- "Love Your Body" sales up 16.9%
 - Now 58% of sales



4 new stores in FY2013, and a further 2 planned in FY2014







TURNOVER



| | % change | % contribution |
|----------------------|----------|----------------|
| Clicks | 9.8 | 32.0 |
| Hospitals | 14.1 | 25.9 |
| Independent pharmacy | (5.6) | 18.1 |
| Other channels | 334.3 | 24.0 |
| Total turnover | 22.8 | 100.0 |

- Volume growth of 23.5%
- Generics +26.7%

PERFORMANCE



- UPD manages total turnover of R11.5 billion
 - 154 million units
- Significant player in the bulk distribution market
 - Portfolio of 20 distribution clients
 - R3.8bn notional turnover in FY2013
- Margin pressure from growth in generics
 - Generics now 36.9% of wholesale medicines
- Wholesale market share increased from 24.3% to 26.7%*



DAVID KNEALE

OUTLOOK

- Muted consumer spending growth to continue
- Selling price inflation expected to be 4% 5%
- Clicks
 - Leverage investment in pharmacy
 - Optimise the ClubCard programme
 - Increase private label penetration
 - Continue to expand store footprint
- UPD
 - Leverage efficiencies from investment in wholesale automation
 - Increase distribution capacity to enable further growth from 2015



DISCLAIMER

Clicks Group has acted in good faith and has made every reasonable effort to ensure the accuracy and completeness of the information contained in this presentation, including all information that may be defined as 'forward-looking statements' within the meaning of United States securities legislation.

Forward-looking statements may be identified by words such as 'believe', 'anticipate', 'expect', 'plan', 'estimate', 'intend', 'project', 'target', 'predict' and 'hope'.

Forward-looking statements are not statements of fact, but statements by the management of Clicks Group based on its current estimates, projections, expectations, beliefs and assumptions regarding the group's future performance.

No assurance can be given that forward-looking statements will prove to be correct and undue reliance should not be placed on such statements.

The risks and uncertainties inherent in the forward-looking statements contained in this presentation include, but are not limited to: changes to IFRS and the interpretations, applications and practices subject thereto as they apply to past, present and future periods; domestic business and market conditions; changes in the domestic regulatory and legislative environments; changes to domestic operational, social, economic and political risks; and the effects of both current and future litigation.

Clicks Group does not undertake to update any forward-looking statements contained in this presentation and does not assume responsibility for any loss or damage whatsoever and howsoever arising as a result of the reliance by any party thereon, including, but not limited to, loss of earnings, profits, or consequential loss or damage.